B

    Bio-Rad Laboratories Inc (BIO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $386.46
    -1.24 (-0.32%)

    Market Cap: $10.38B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +13.43%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.23
    Range$2.12 - $2.35
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$2.51+12.4%
    60d ago$2.31+3.6%
    30d ago$2.31+3.6%
    7d ago$2.31+3.6%
    Current$2.23
    Revenue Consensus
    $651M
    Range$647M - $656M
    4 analysts
    Dec 31, 2026
    EPS Consensus$3.52
    Range$2.89 - $4.14
    5 analysts
    Revenue Consensus
    $710M
    Range$669M - $731M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.52---
    Sep 26EST
    		-$2.23---
    Jun 26
    		$2.62$2.34+11.97%Beat+0.4%
    Mar 26
    		$1.89$1.99-5.03%Miss-25.6%
    Dec 25
    		$2.51$2.70-7.04%Miss-13.4%
    Sep 25
    		$2.26$1.93+17.10%Beat+12.4%
    Jun 25
    		$2.61$1.75+49.14%Beat-16.1%
    Mar 25
    		$2.54$1.78+42.70%Beat+10.9%
    Dec 24
    		$2.90$2.88+0.69%Beat-6.5%
    Sep 24
    		$2.01$1.18+70.34%Beat-13.7%
    Jun 24
    		$3.11$2.02+53.96%Beat+3.7%
    Mar 24
    		$2.29$2.14+7.01%Beat-31.4%
    Dec 23
    		$3.10$2.87+8.01%Beat-6.3%
    Sep 23
    		$2.33$2.81-17.08%Miss-10.4%
    Jun 23
    		$3.00$2.68+11.94%Beat-11.2%
    Mar 23
    		$3.34$3.48-4.02%Miss-32.4%
    Dec 22
    		$3.31$3.44-3.78%Miss+3.1%
    Sep 22
    		$2.60$2.77-6.14%Miss-29.9%
    Jun 22
    		$3.38$2.77+22.02%Beat-4.5%
    Mar 22
    		$4.94$3.23+52.94%Beat-5.2%
    Dec 21
    		$3.21$2.87+11.85%Beat-20.0%
    Sep 21
    		$3.71$2.48+49.60%Beat+23.7%
    Jun 21
    		$3.54$2.70+31.11%Beat+119.9%
    Mar 21
    		$5.21$2.94+77.21%Beat+172.8%
    Dec 20
    		$4.01$3.32+20.78%Beat+72.8%
    Sep 20
    		$3.00$1.82+64.84%Beat+86.3%
    Jun 20
    		$1.61$1.15+40.00%Beat+2.5%
    Mar 20
    		$1.91$1.57+21.66%Beat+15.8%
    Dec 19
    		$2.32$2.45-5.31%Miss+8.9%
    Sep 19
    		$1.61$1.41+14.18%Beat+76.9%
    Jun 19
    		$1.57$1.34+17.16%Beat-4.3%
    Mar 19
    		$1.65$1.09+51.38%Beat+65.0%
    Dec 18
    		$2.13$1.70+25.29%Beat+317.6%
    Sep 18
    		$0.91$1.14-20.18%Miss+0.0%
    Jun 18
    		$1.64$1.28+28.13%Beat+864.7%
    Mar 18
    		$1.00$1.22-18.03%Miss+143.9%
    Dec 17
    		$0.51N/A-59.52%Miss+172.9%
    Sep 17
    		$0.91$0.60+51.67%Beat+46.8%
    Jun 17
    		$0.17N/A-75.00%Miss-
    Mar 17
    		$0.41$0.27+51.85%Beat-
    Dec 16
    		$-0.70$1.03-167.96%Miss-
    Sep 16
    		$0.62$0.51+21.57%Beat-

    Key Metrics

    Valuation
    P/E Ratio41.64EV/EBITDA17.70x
    Price/FCF26.33xFCF Yield3.80%
    Profitability
    Profit Margin8.59%Operating Margin11.20%
    ROE3.11%ROIC1.12%
    Financial Health
    Debt/Equity0.17xInterest Coverage2.94x
    Current Ratio3.14xQuick Ratio2.33x
    Trading Statistics
    Beta1.05Avg Volume270.62K
    52-Week High$396.2352-Week Low$236.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$379.83
    SMA 20$365.97
    SMA 50$327.94
    SMA 200$300.59
    EMA 10$379.85
    EMA 20$366.36
    EMA 50$338.69
    EMA 200$303.55

    MACD

    Line: 17.86Signal: 17.19Hist: 0.66

    ADX

    ADX: 50.9+DI: 31.8-DI: 7.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$370.58

    Bollinger Bands

    Upper Band$401.34
    Lower Band$330.60
    %B Position1933%(Upper)
    Band Width0.79

    RSI (14-Day)

    Overbought
    75.0

    Momentum Oscillators

    Stoch %K82.4
    Stoch %D87.3
    Williams %R-21.6
    ROC (10d)8.8%
    Momentum31.23
    CCI (20d)96.5
    MFI (14d)60.6

    Volatility Measures

    ATR (14d)$11.03(2.9%)
    StdDev (20d)17.69
    Hist Vol27.1%(Moderate)

    Volume Flow

    VWAP$387.20
    OBV2.1M
    AD Line8.4M
    CMF (20d)0.290

    Volume Metrics

    Avg Vol (20d)269.4K
    Vol Ratio1.1x
    VWMA (20d)$365.68

    Pivot Points

    R3$402.81
    R2$397.55
    R1$392.63
    Pivot Point$387.36
    S1$382.44
    S2$377.18
    S3$372.25

    Advanced Oscillators

    TSI52.74
    Ultimate Osc61.1
    KST191.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$651.00M$592.10M$693.20M$653.00M$651.60M$585.40M$667.50M$649.70M$638.50M$610.80M$681.12M$632.12M
    Cost of Revenue$305.20M$282.70M$348.00M$309.60M$306.30M$279.40M$325.50M$293.80M$283.40M$284.90M$314.81M$296.44M
    Gross Profit$345.80M$309.40M$345.20M$343.40M$345.30M$306.00M$342.00M$355.90M$355.10M$325.90M$366.32M$335.68M
    Operating Expenses$273.20M$275.30M$464.10M$278.10M$268.20M$282.30M$283.60M$291.40M$253.60M$281.30M$271.00M$244.73M
    R&D$61.20M$62.90M$70.30M$71.30M$60.50M$73.50M$79.60M$91.00M$58.90M$66.40M$63.87M$43.53M
    SG&A$212.00M$212.40M$221.00M$206.80M$207.70M$208.80M$204.00M$200.40M$194.70M$214.90M$207.12M$201.20M
    Operating Income$72.60M$34.10M$-118,900,000$65.30M$77.10M$23.70M$58.40M$64.50M$101.50M$44.60M$95.32M$90.95M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$12.10M$12.30M$12.10M$12.30M$12.60M$12.00M$12.20M$12.10M$12.30M$12.30M$12.32M$12.40M
    Income Before Tax$542.10M$-689,800,000$929.20M$-431,100,000$414.00M$83.40M$-908,900,000$861.60M$-2,786,300,000$491.10M$428.40M$137.10M
    Income Tax Expense$170.70M$-162,700,000$209.20M$-89,200,000$96.20M$19.40M$-193,100,000$208.40M$-620,800,000$107.20M$78.66M$30.84M
    Net Income$371.40M$-527,100,000$720.00M$-341,900,000$317.80M$64.00M$-715,800,000$653.20M$-2,165,500,000$383.90M$349.73M$106.26M
    EBITDA$554.20M$-677,500,000$40.90M$-418,800,000$426.60M$95.40M$1.76B$873.70M$-2,774,000,000$503.40M$1.69B$149.50M
    EBIT$554.20M$-677,500,000$40.90M$-418,800,000$426.60M$95.40M$1.76B$873.70M$-2,774,000,000$503.40M$1.69B$149.50M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIO

    News

    Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends

    Bio-Rad Laboratories' stock is up 6.7% following a restructuring announcement aimed at cost savings and improving operating margins by 2027. This move comes as the company experiences continued growth in its digital PCR business but faces softer demand in its Life Science segment and maintains a cautious outlook for 2026. The restructuring is a key factor in the investment narrative, addressing concerns about gross margin pressure and low returns, but investors should be aware of the risks if savings fall short or market conditions remain weak.

    Sahm•8/24/26•
    Neutral

    Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA

    This article displays the "Return on invested capital %" for Bio-Rad Laboratories, Inc. Class A (HAM:BUWA). The content is primarily a data page from TradingView, focusing on the financial metric for the specified company listed on the Hamburg Stock Exchange.

    TradingView•8/22/26•
    Neutral

    EBITDA per share of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA

    The article focuses on the EBITDA per share information for Bio-Rad Laboratories, Inc. Class A (HAM:BUWA) as presented on TradingView. It appears to be a page from a financial data platform, providing an overview of the company's financials for users. The content includes navigation and legal disclaimers related to the financial data provided.

    TradingView•8/21/26•
    Neutral

    Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value?

    Bio-Rad Laboratories (BIO) has seen a sharp increase in its stock price over the last 90 days, despite recent flat revenue guidance and a significant long-term decline in shareholder return. The company is currently trading above its fair value estimate of $293, driven by robust order growth in biopharmaceutical research, but faces challenges from softer instrument demand. Investors are advised to review the data to form their own views on the company's valuation.

    Sahm•8/13/26•
    Somewhat-Bearish

    Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses

    Bio-Rad Laboratories reported flat net sales of $651.0 million in Q2 2026, with a significant net income of $371.4 million driven by a large fair-value gain on equity securities and a loan receivable, primarily related to its Sartorius investment. However, the first half of 2026 saw a net loss of $155.7 million due to a $280.2 million fair-value loss on these assets. The company announced a restructuring plan starting in July 2026, expected to incur $80-90 million in pre-tax charges through 2027, and maintains strong liquidity with $1.62 billion in cash and no borrowings on its credit facility.

    Stock Titan•8/5/26•
    Somewhat-Bearish

    Frequently Asked Questions About BIO

    Does BIO pay dividends?
    Bio-Rad Laboratories Inc (BIO) does not currently pay a regular dividend.
    What is BIO's P/E ratio?
    Bio-Rad Laboratories Inc has a price-to-earnings (P/E) ratio of 41.64.
    What is BIO's market cap?
    Bio-Rad Laboratories Inc (BIO) has a market capitalization of $10.38B with a current stock price of $386.46.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In